JP2024521791A5 - - Google Patents
Info
- Publication number
- JP2024521791A5 JP2024521791A5 JP2023572825A JP2023572825A JP2024521791A5 JP 2024521791 A5 JP2024521791 A5 JP 2024521791A5 JP 2023572825 A JP2023572825 A JP 2023572825A JP 2023572825 A JP2023572825 A JP 2023572825A JP 2024521791 A5 JP2024521791 A5 JP 2024521791A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- egfr
- cancer
- composition according
- mediated cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193574P | 2021-05-26 | 2021-05-26 | |
| US63/193,574 | 2021-05-26 | ||
| US202163270488P | 2021-10-21 | 2021-10-21 | |
| US63/270,488 | 2021-10-21 | ||
| PCT/US2022/031193 WO2022251539A2 (en) | 2021-05-26 | 2022-05-26 | Egfr degraders to treat cancer metastasis to the brain or cns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521791A JP2024521791A (ja) | 2024-06-04 |
| JP2024521791A5 true JP2024521791A5 (https=) | 2025-06-03 |
Family
ID=84230313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572825A Pending JP2024521791A (ja) | 2021-05-26 | 2022-05-26 | 脳又はｃｎｓへの癌転移を治療するためのｅｇｆｒデグレーダー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240158418A1 (https=) |
| EP (1) | EP4347044A4 (https=) |
| JP (1) | JP2024521791A (https=) |
| KR (1) | KR20240019099A (https=) |
| AU (1) | AU2022280070A1 (https=) |
| BR (1) | BR112023024507A2 (https=) |
| CA (1) | CA3174207A1 (https=) |
| IL (1) | IL308182A (https=) |
| MX (1) | MX2023014061A (https=) |
| TW (1) | TW202313025A (https=) |
| WO (1) | WO2022251539A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP4735452A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras protein |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| CN117503737B (zh) * | 2024-01-05 | 2024-04-16 | 成都金瑞基业生物科技有限公司 | 和厚朴酚在制备治疗脂肪肉瘤药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017164887A1 (en) * | 2016-03-25 | 2017-09-28 | OSI Pharmaceuticals, LLC | Pulse dosing regimen and methods for treatment |
| PE20211388A1 (es) * | 2018-06-29 | 2021-07-27 | Hoffmann La Roche | Compuestos |
| IL288522B2 (en) * | 2019-06-21 | 2025-02-01 | Hoffmann La Roche | EGFR inhibitor for cancer treatment |
| KR20220119415A (ko) * | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
-
2022
- 2022-05-26 CA CA3174207A patent/CA3174207A1/en active Pending
- 2022-05-26 MX MX2023014061A patent/MX2023014061A/es unknown
- 2022-05-26 BR BR112023024507A patent/BR112023024507A2/pt unknown
- 2022-05-26 AU AU2022280070A patent/AU2022280070A1/en active Pending
- 2022-05-26 KR KR1020237041044A patent/KR20240019099A/ko active Pending
- 2022-05-26 WO PCT/US2022/031193 patent/WO2022251539A2/en not_active Ceased
- 2022-05-26 IL IL308182A patent/IL308182A/en unknown
- 2022-05-26 JP JP2023572825A patent/JP2024521791A/ja active Pending
- 2022-05-26 TW TW111119753A patent/TW202313025A/zh unknown
- 2022-05-26 EP EP22812189.3A patent/EP4347044A4/en active Pending
-
2023
- 2023-11-21 US US18/516,589 patent/US20240158418A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521791A5 (https=) | ||
| JP2023509375A5 (https=) | ||
| US12319670B2 (en) | Compounds and methods for inhibiting JAK | |
| AU2011336397B2 (en) | Chemokine CXCR4 receptor modulators and uses related thereto | |
| JP2016523973A5 (https=) | ||
| AU2004257260A1 (en) | Substituted heterocyclic diarylamine analogues | |
| BR112017007769B1 (pt) | Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos | |
| JP2017503813A5 (https=) | ||
| JP2013056930A5 (https=) | ||
| JP2018503648A (ja) | ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体 | |
| JP2011509307A5 (https=) | ||
| JP2018518522A (ja) | 癌を治療するための組成物及び方法 | |
| JP2020536971A5 (https=) | ||
| JP2016525104A5 (https=) | ||
| US20240245634A1 (en) | Pcna inhibitors and egfr inhibitors for cancer treatment | |
| CN1511036A (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| RU2009149518A (ru) | Триазоло[1, 5-а]хинолины в качестве лигандов рецептора аденозина а3 | |
| US20220218666A1 (en) | Application of tegaserod in preparation of anti-tumor drug | |
| CN115279373A (zh) | Egfr/her2的氰基嘧啶抑制剂 | |
| US20210000830A1 (en) | CANCER TREATMENT METHOD USING Trk INHIBITOR AND KINASE INHIBITOR IN COMBINATION | |
| RU2023130604A (ru) | Рецепторы эпидермального фактора роста для лечения метастазов рака в головной мозг или центральную нервную систему | |
| CN119320352B (zh) | hnRNPA2B1激动剂及其与STING激动剂联用的肿瘤防治应用 | |
| CN119320354B (zh) | hnRNPA2B1激动剂及其与化疗剂联用的肿瘤防治应用 | |
| CN119320353B (zh) | hnRNPA2B1激动剂化合物及其肿瘤防治应用 | |
| JP7768770B2 (ja) | Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤 |